Literature DB >> 20609474

Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.

Pierre Fenaux1, David Bowen, Norbert Gattermann, Eva Hellström-Lindberg, Wolf-Karsten Hofmann, Michael Pfeilstöcker, Guillermo Sanz, Valeria Santini.   

Abstract

Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals. However, several aspects of the practical use of azacitidine remain uncertain. This manuscript outlines recommendations discussed by a panel of experts, providing a practical guide for physicians to ensure optimal management of Int-2 and high-risk patients receiving azacitidine.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20609474     DOI： 10.1016/j.leukres.2010.05.021

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  15 in total

Review 1.  Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes.

Authors:  Shyamala C Navada; Lewis R Silverman
Journal:  Ther Adv Hematol       Date:  2016-10-20

Review 2.  Infections in myelodysplastic syndromes.

Authors:  Andréa Toma; Pierre Fenaux; François Dreyfus; Catherine Cordonnier
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

3.  Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia.

Authors:  Christine Valentiny; Martina Mitrovic; Lisa Pleyer; Michael Steurer; Wolfgang Willenbacher; Reinhard Stauder
Journal:  Wien Klin Wochenschr       Date:  2013-01-05       Impact factor: 1.704

Review 4.  Current therapy of myelodysplastic syndromes.

Authors:  Amer M Zeidan; Yuliya Linhares; Steven D Gore
Journal:  Blood Rev       Date:  2013-07-27       Impact factor: 8.250

5.  Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.

Authors:  Yoo-Jin Kim; Jun Ho Jang; Jae-Yong Kwak; Je-Hwan Lee; Hyeoung-Joon Kim
Journal:  Blood Res       Date:  2013-06-25

6.  A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial.

Authors:  Steven D Gore; Pierre Fenaux; Valeria Santini; John M Bennett; Lewis R Silverman; John F Seymour; Eva Hellström-Lindberg; Arlene S Swern; Charles L Beach; Alan F List
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

Review 7.  Stopping higher-risk myelodysplastic syndrome in its tracks.

Authors:  Daniel A Pollyea; Jonathan A Gutman
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

8.  Treatment of chronic myelomonocytic leukemia with 5-azacytidine: case reports.

Authors:  Peter Rohon; Jana Vondrakova; Anna Jonasova; Milena Holzerova; Marie Jarosova; Karel Indrak
Journal:  Case Rep Hematol       Date:  2012-05-28

Review 9.  The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients.

Authors:  Reinhard Stauder
Journal:  Ann Hematol       Date:  2012-05-01       Impact factor: 3.673

Review 10.  Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2012-05-28       Impact factor: 11.431
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.